Literature DB >> 1671433

Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus.

A L Benabid1, P Pollak, C Gervason, D Hoffmann, D M Gao, M Hommel, J E Perret, J de Rougemont.   

Abstract

The usefulness of high-frequency stimulation of the ventral intermediate nucleus (Vim) as the first neurosurgical procedure in disabling tremor was assessed in 26 patients with Parkinson's disease and 6 with essential tremor. 7 of these patients had already undergone thalamotomy contralateral to the stimulated side, and 11 others had bilateral Vim stimulation at the same time. Chronic stimulating electrodes connected to a pulse generator were implanted in the Vim. Tremor amplitude at rest, during posture holding, and during action and intention manoeuvres was assessed by means of accelerometry. Of the 43 thalami stimulated, 27 showed complete relief from tremor and 11 major improvement (88%). The improvement was maintained for up to 29 months (mean follow-up 13 [SD 9] months). Adverse effects were mild and could be eradicated by reduction or cessation of stimulation. This reversibility and adaptability, allowing control of side-effects, make thalamic stimulation preferable to thalamotomy, especially when treatment of both sides of the brain is needed.

Entities:  

Mesh:

Year:  1991        PMID: 1671433     DOI: 10.1016/0140-6736(91)91175-t

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  302 in total

1.  Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex.

Authors:  D Caparros-Lefebvre; S Blond; M P Feltin; P Pollak; A L Benabid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Deep brain stimulation of the subthalamic nucleus: anatomical, neurophysiological, and outcome correlations with the effects of stimulation.

Authors:  M M Lanotte; M Rizzone; B Bergamasco; G Faccani; A Melcarne; L Lopiano
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

3.  Impact of thalamic deep brain stimulation on disability and health-related quality of life in patients with essential tremor.

Authors:  G-M Hariz; M Lindberg; A T Bergenheim
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

Review 4.  Neural prostheses.

Authors:  A Prochazka; V K Mushahwar; D B McCreery
Journal:  J Physiol       Date:  2001-05-15       Impact factor: 5.182

5.  A Wearable System for Attenuating Essential Tremor Based on Peripheral Nerve Stimulation.

Authors:  Jeonghee Kim; Thomas Wichmann; Omer T Inan; Stephen P Deweerth
Journal:  IEEE J Transl Eng Health Med       Date:  2020-04-06       Impact factor: 3.316

6.  Multicentre European study of thalamic stimulation in essential tremor: a six year follow up.

Authors:  O Sydow; S Thobois; F Alesch; J D Speelman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-10       Impact factor: 10.154

7.  MRI directed bilateral stimulation of the subthalamic nucleus in patients with Parkinson's disease.

Authors:  N K Patel; P Plaha; K O'Sullivan; R McCarter; P Heywood; S S Gill
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

Review 8.  Surgical therapy for dystonia.

Authors:  Helen Bronte-Stewart
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

Review 9.  Toward Electrophysiology-Based Intelligent Adaptive Deep Brain Stimulation for Movement Disorders.

Authors:  Andrea A Kühn; R Mark Richardson; Wolf-Julian Neumann; Robert S Turner; Benjamin Blankertz; Tom Mitchell
Journal:  Neurotherapeutics       Date:  2019-01       Impact factor: 7.620

Review 10.  Deep Brain Stimulation for Movement Disorders of Basal Ganglia Origin: Restoring Function or Functionality?

Authors:  Thomas Wichmann; Mahlon R DeLong
Journal:  Neurotherapeutics       Date:  2016-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.